Cargando…

Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse

This study investigated the kinetics in HBsAg and the HBsAg loss rate after entecavir or tenofovir disoproxil fumarate (TDF) cessation in patients with chronic hepatitis B (CHB) who achieved virological suppression after virological relapse without clinical relapse. A total 504 HBeAg-negative, non-c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tseng, Tzu-Ning, Kuo, Yuan-Hung, Hu, Tsung-Hui, Hung, Chao-Hung, Wang, Jing-Houng, Lu, Sheng-Nan, Chen, Chien-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227936/ https://www.ncbi.nlm.nih.gov/pubmed/35746660 http://dx.doi.org/10.3390/v14061189

Ejemplares similares

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
por: Galati, Giovanni, et al.
Publicado: (2014)

Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL
por: Yao, Chih-Chien, et al.
Publicado: (2017)

A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort
por: Yen, Yi-Hao, et al.
Publicado: (2018)

Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function
por: Chien, Tai-Long, et al.
Publicado: (2016)

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023)

Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B
por: Song, Joon Chang, et al.
Publicado: (2011)

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment
por: Ma, Te-Ling, et al.
Publicado: (2019)

MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin
por: Yen, Yi-Hao, et al.
Publicado: (2016)

Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection
por: Su, Tung-Hung, et al.
Publicado: (2013)

Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Coexistence of HBsAg and Anti-HBs
por: Liu, Yong, et al.
Publicado: (2016)

Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients
por: Cheng, Huei-Ru, et al.
Publicado: (2013)

Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
por: Kim, Kwang Min, et al.
Publicado: (2011)

Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection
por: Gantner, Pierre, et al.
Publicado: (2019)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis
por: ZHANG, LIN L., et al.
Publicado: (2020)

B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

What are the causes and outcomes of the coexistence of HBsAg and anti-HBs?
por: Afyon, Murat
Publicado: (2016)

Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels
por: Lam, Yuk-Fai, et al.
Publicado: (2017)

Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection
por: Yan, Ying, et al.
Publicado: (2022)

Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B
por: Kwak, Min-Sun, et al.
Publicado: (2019)

Comparison of Serum HBsAg Quantitation by Four Immunoassays, and Relationships of HBsAg Level with HBV Replication and HBV Genotypes
por: Tuaillon, Edouard, et al.
Publicado: (2012)

Assessment of noninvasive liver stiffness in inactive HBsAg carriers by transient elastography: Fibroscan in inactive HBsAg carriers
por: Sporea, Ioan, et al.
Publicado: (2011)

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro
por: Salpini, Romina, et al.
Publicado: (2017)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
por: Jiang, Shaowen, et al.
Publicado: (2023)

HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation
por: Xie, Yandi, et al.
Publicado: (2021)

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation
por: Xie, Yandi, et al.
Publicado: (2023)

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

AUSTRALIA ANTIGEN (HBsAG) IN INSTITUTIONALISED SCHIZOPHRENICS
por: Chaudhury, S., et al.
Publicado: (1993)

HBsAg seroprevalence among Senegalese militaries
por: Ndiaye, Abdoul A, et al.
Publicado: (2015)

Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir
por: Lim, Jung Hyun, et al.
Publicado: (2021)

Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results
por: Lee, Jaehyeon, et al.
Publicado: (2023)

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers
por: Roade, Luisa, et al.
Publicado: (2023)

The Changes of Liver Stiffness and Its Associated Factors for Chronic Hepatitis B Patients with Entecavir Therapy
por: Kuo, Yuan-Hung, et al.
Publicado: (2014)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
por: Yan, Lei, et al.
Publicado: (2018)

Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss
por: Wu, I-Chin, et al.
Publicado: (2021)

Frequency of Detectable HBsAg in Fluid Adherent to the Endoscope, Gastric Juice, and Saliva Collected during Endoscopy in Patients Positive for HBsAg
por: Yang, Ung-Suk, et al.
Publicado: (1986)

A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation
por: Hung, Chao-Hung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_33hfu3i71gitl9rofi7m12v6o5